Thermosensitive nanomedicines could revolutionize thermal therapy in oncology

Abstract Technologies that enable thermal therapy treatments are now clinically viable and most ongoing hyperthermia clinical trials in oncology incorporate chemotherapy. Given the extensive list of chemotherapies that are enhanced by hyperthermia and the ability of thermosensitive nanomedicines to deliver increased amounts of drug to tumors, while not relying on the EPR effect, there is real opportunity for the clinical translation of thermosensitive nanomedicines. To realize this potential, improved thermosensitive nanomedicines encapsulating a wider range of drugs must be developed and advanced into clinical trials.